SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Novo Nordisk A/S is a global healthcare company, which engages in the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Rare Disease segments. The Diabetes and Obesity Care segment includes diabetes, obesity, cardiovascular, and emerging therapy areas. The Rare Disease segment refers to rare blood disorders, rare endocrine disorders, and hormone replacement therapy. The company was founded by Harald Pedersen and Thorvald Pedersen in 1923 is headquartered in Bagsværd, Denmark.

Novo Nordisk - ADR

Novo Nordisk A/S

Novo Nordisk is trending as the community discusses the implications of the company's recent Phase III trial failure for its Alzheimer's drug, with some investors expressing disappointment while others see it as an opportunity to buy. Despite the setback, there is optimism surrounding Novo Nordisk's position in the weight loss market, particularly with the potential upcoming approval of its oral Wegovy pill and comparison of CagriSema vs Zepbound study results.

JPMorgan Chase & Co. is a financial holding company, which engages in the provision of financial and investment banking services. It focuses on investment banking, financial services for consumers and small businesses, commercial banking, financial transaction processing, and asset management. It operates through the following segments: Consumer and Community Banking (CCB), Commercial and Investment Bank (CIB), Asset and Wealth Management (AWM), and Corporate. The CCB segment originates and services mortgage loans. The CIB segment makes markets and services clients across fixed income, foreign exchange, equities, and commodities. The AWM segment provides initial capital investments in products such as mutual funds and capital invested alongside third-party investors. The Corporate segment manages its liquidity, funding, capital, structural interest rate, and foreign exchange risks. The company was founded in 1799 and is headquartered in New York, NY.

JPMorgan Chase & Co.

JPMorgan Chase & Co

JPMorgan Chase is trending amid mixed sentiment, as discussions range from its ties to controversial figures to its evolving stance on cryptocurrency and potential competition with Bitcoin. The community is actively debating JPMorgan's investment strategies, alleged market manipulation, and the implications of its exploration of blockchain technology and stablecoins. Additionally, some traders are monitoring technical indicators to predict JPM's short-term price movements, while others are discussing potential investigations and regulatory scrutiny.

Pony.ai, Inc. develops artificial intelligence-based robot designed for autonomous driving. The firm's software algorithms and infrastructure enables a vehicle to perceive its surroundings, predict what others will do, and maneuver itself accordingly. The company was founded by Jun Peng and Tian Cheng Lou in November 4, 2016 and is headquartered in Guangzhou, China.

Pony AI Inc. - ADR

Pony AI Inc

Pony AI is trending due to news of expanded robotaxi operations and partnerships, including a recent permit in Shanghai. The community is weighing the company's growth prospects against its financial performance, especially regarding profitability targets. Broader discussions involve comparing Pony AI to competitors in the autonomous driving space and assessing the impact of these developments on its market position.

Monad

Monad is trending as users discuss its upcoming launch and token distribution, particularly excitement around receiving tokens from the Coinbase presale. The community is actively speculating on potential price movements and strategies, with some comparing it to other recent launches. There's also discussion around the mainnet launch date.

WeRide, Inc. operates as an investment holding company. It engages in the sale of autonomous driving vehicles, primarily including robobuses, robotaxis, robosweepers and related sensor suites. The company was founded by Tony Xu Han and Yan Li in February 2017 and is headquartered in Guangzhou, China.

WeRide Inc. - ADR

WeRide is trending due to strong Q3 2025 earnings, highlighted by a 144.3% YoY revenue increase and significant growth in robotaxi revenue, with community members noting global expansion and regulatory milestones in the UAE and Switzerland. Investors are focused on WeRide's progress toward deploying hundreds of thousands of robotaxis by 2030 and its partnerships with companies like Bosch, Uber, and Grab. The conversation also includes comparisons to competitor Pony.ai, whose stock performance and institutional ownership are being weighed against WeRide's recent gains and expansion efforts.

Diginex Ltd. (Hong Kong) is a blockchain financial services and technology company. Its products include diginexESG, diginexLUMEN, diginexAPPRISE, diginexLUMEN Pro, and CSRD framework. The company was founded by Miles Christian Pelham on May 15, 2020 and is headquartered in London, the United Kingdom.

Diginex Ltd.

DGNX is trending due to its recent acquisition of The Remedy Project, sparking discussions about the company's expansion into human-rights remediation. The community is also actively analyzing potential trading strategies based on historical patterns of similar stocks. Options traders are closely monitoring put contracts, anticipating potential downside amidst the volatility.

Oscar Health, Inc. is a health insurance company, which serves its customers through a technology platform. It offers individual and family, small group and medicare advantage plans, and technology platform to others within the provider and payor space. The company was founded by Mario Tobias Schlosser, Kevin Nazemi, and Joshua Kushner on October 25, 2012 and is headquartered in New York, NY.

Oscar Health Inc - Ordinary Shares - Class A

Oscar Health is trending amid uncertainty surrounding the Affordable Care Act (ACA) subsidies, with discussions focusing on potential impacts from Trump's healthcare proposals. The community is weighing the company's prospects with or without the subsidies, while some highlight Oscar Health's cash position and potential for growth in individual health plans. Options traders are active, with both bullish call buying and bearish put buying strategies being discussed.

Alvotech is a biotechnology company, which engages in the development and manufacture of biosimilar medicines. The firm is focusing on the development of its product candidates. It operates through the following geographical segments: Europe, North America, Asia, and Other. The company was founded by Róbert Vilhelm Wessman in 2013 and is headquartered in Luxembourg.

Alvotech

Alvotech ($ALVO) is trending following the announcement of European approval for AVT03, a biosimilar to Prolia and Xgeva, used in bone disease treatment, sparking bullish sentiment. Despite some community concerns about cash flow and previous manufacturing setbacks, the biosimilar's approval and analyst upgrades are fueling optimism. Discussions center on the company's potential in the biosimilar market and strategic partnerships.

Meet Pandu — your AI friend who’s always by your side. Talk with him in real time through text or voice, share your thoughts, ask questions, or just enjoy a casual conversation. Whether you’re looking for advice, company, or simply someone to listen, Pandu is here as a true companion you can connect with anytime.  Pandu unites real-time conversation, creative generation, and future-ready AI systems — all powered by next-gen technology.

Pandu Pandas

Pandu Pandas ($PANDU) is gaining attention, with community members highlighting recent updates and increased market interest. The community emphasizes the project's potential, strong fundamentals, transparent communication, and clear utility development, with some anticipating significant growth. Discussions also touch on the token's low market cap, growing holder base, and potential for a breakout, particularly within the Solana ecosystem.

Sanofi engages in the research, production, and distribution of pharmaceutical products. It operates through the Biopharma segment, which comprises commercial operations and research, development and production activities relating to the specialty care, general medicines and vaccines franchises plus support and corporate functions, for all geographical territories. The company was founded in 1973 and is headquartered in Paris, France.

Sanofi - ADR

Sanofi-Aventis

Sanofi-Aventis ($SNY) is trending amid speculation surrounding potential acquisitions, particularly in the MASH and obesity spaces, with $ALT, $GUTS, and $IVA being mentioned as possible targets. Community discussions revolve around the company's pipeline expansion needs and potential partnerships, with some users highlighting data integrity concerns around one of the speculated targets. The broader context involves Sanofi's strategic moves to strengthen its immunology and vaccine portfolio.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

Wednesday, 13 August 2025 08:30 AMTopic:&nbsp;<h4>Company Update</h4>&nbsp;TAMPA, FLORIDA / <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.accessnewswire.com/">ACCESS Newswire</a> / August 13, 2025 / Wellgistics Health, Inc. (NASDAQ:WGRX) ("Wellgistics Health" or the "Company"), a leader in next-generation pharmaceutical distribution, digital prescription routing, and AI-powered hub fulfillment, today announced the launch of its Ripple Labs-powered XRP Implementation Program, giving independent pharmacies access to blockchain-based payments in the prescription drug space for the first time. The program enables pharmacies to pay for products and move funds instantly, more cost-effectively, and with full transparency-eliminating delays, high fees, and reliance on traditional banking and credit card networks. Wellgistics Health is among the first healthcare companies to implement an XRP-based payment solution at scale.The program operates in partnership with RxERP, a serialized pharmaceutical eCommerce and ERP (Enterprise Resource Planning) system that manages onboarding, transactions, and reporting for participating pharmacies. With Wellgistics already serving more than 6,500 independent pharmacies and over 200 manufacturers nationwide, the Company is well-positioned to accelerate adoption rapidly and at scale.Pharmacies can now enroll in the beta program at:<a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/d8zp">https://wellgisticshealth.com/xrp-in-healthcare/</a>How Pharmacies Benefit from Using XRP<ul><li>Instant Settlement - Payments settle in seconds, not days</li><li>Lower Fees - Avoid credit card and bank transaction costs</li><li>24/7 Availability - No banking delays, even on weekends and holidays</li><li>Improved Cash Flow - Faster access to working capital and inventory restock</li><li>Real-Time Tracking - View and confirm payments instantly</li><li>No Intermediaries - Direct transactions between pharmacy and distributor</li></ul>"We've been impressed with the response so far," said Brian Norton, CEO of Wellgistics Health. "Independent pharmacy owners are far more forward-thinking than many realize. They see the power of blockchain and understand how transformative this will be as it scales across the industry. Our mission is to give pharmacies greater control, speed, and transparency in their financial operations."Technical Innovation and Blockchain IntegrationThe XRP Payment Program harnesses the speed, scalability, and low-cost infrastructure of the XRP Ledger to meet the unique demands of the pharmaceutical supply chain. Integrated with RxERP, the platform delivers real-time, encrypted, and fully compliant payment processing tailored for independent pharmacies, wholesalers and in the near future, manufacturers.Pharmacies and investors can learn more by downloading the Wellgistics Health XRP E-Book:<a target="_blank" rel="noopener noreferrer nofollow" href="https://pr.report/d8zq">https://wellgisticshealth.com/xrp-in-healthcare/</a>Regulatory Compliance and SecurityThe XRP Payment Program has been developed to meet or exceed healthcare and financial regulatory standards, including HIPAA and anti-money laundering (AML) requirements. The system provides secure, traceable transactions while safeguarding sensitive data and maintaining privacy at every stage.Next Phase: Manufacturer Onboarding and Direct-to-Patient (DTP) ProgramsFollowing the pharmacy rollout, Wellgistics Health will begin onboarding pharmaceutical manufacturers to the XRP platform-expanding capabilities for direct, on-chain transactions. The Company also plans to launch manufacturer-powered Direct-to-Patient (DTP) programs, allowing manufacturers to ship medications directly to patients' homes in collaboration with their community pharmacy and prescribing physicians to ensure clinical continuity and compliance."Pharmacies deserve a payment system as fast and responsive as the care they provide," said Tony Madsen, COO of Wellgistics Health. "While this first phase focuses on helping pharmacies pay for products more efficiently, it's just the start. Our vision is to make every aspect of pharmacy payments faster, clearer, and completely frictionless."About Wellgistics HealthWellgistics Health (NASDAQ: WGRX) delivers medications from manufacturer to patient-faster, smarter, and more affordably. Its integrated platform connects 6,500+ independent pharmacies and 200+ U.S. manufacturers, providing wholesale distribution, digital prescription routing, and AI-powered hub services such as eligibility, adherence, onboarding, prior authorization, and cash-pay fulfillment. As a PBM-agnostic alternative, Wellgistics Health offers compliant, end-to-end solutions that restore access, transparency, and trust in U.S. healthcare.About RxERPRxERP is the only serialized pharmaceutical ERP system designed specifically for independent pharmacies, wholesalers, and manufacturers. It delivers real-time financial, operational, and compliance tools-integrating blockchain, AI, and serialized inventory management to streamline operations and modernize the supply chain. RxERP is the platform partner managing the XRP Implementation Program with Wellgistics Health.Forward-Looking StatementsThis press release may contain forward-looking statements regarding Wellgistics Health's plans, strategies, future operations, and expected performance. These statements are based on current expectations and involve risks and uncertainties that may cause actual results to differ materially. Factors that could affect these results include, but are not limited to, market conditions and risks detailed in filings with the SEC. Investors are cautioned not to place undue reliance on forward-looking statements. Additional information is available at www.sec.gov.Media Contact: <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:media@wellgisticshealth.com">media@wellgisticshealth.com</a> Investor Relations: <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:investors@wellgisticshealth.com">investors@wellgisticshealth.com</a>Investor Relations Contact: Skyline Corporate Communications Group, LLC Scott Powell, President 1177 Avenue of the Americas, 5th Floor New York, NY 10036 Office: (646) 893-5835 Email: <a target="_blank" rel="noopener noreferrer nofollow" href="mailto:info@skylineccg.com">info@skylineccg.com</a>SOURCE: Wellgistics Health, Inc.Note: This article has been published automatically by sourcing from Access Newswire. The Stocktwits editorial team did not edit this article.

Wellgistics Health (NASDAQ: WGRX) Launches XRP Payment Program for Independent Pharmacies

https://www.accessnewswire.com/newsroom/en/blockchain-and-cryptocurrency/wellgistics-health-nasdaq-wgrx-launches-xrp-payment-program-for-indep-1060334

Others

Wellgistics Health, Inc., a holding company focused on pharmaceuticals and healthcare services, has drawn significant retail investor attention since going public on Feb. 21.&nbsp;Despite closing below its $4.50 IPO price on day one, the Tampa, Florida-based company has seen its Stocktwits follower count surge by over 960%, with a six-fold increase in the last week alone, the highest for any healthcare firm on Stocktwits during this period.Message volume on the platform about the stock has also skyrocketed by 10,800% since its market debut.So, what's fueling the buzz? Let's break down the key developments since the IPO.Strategic Partnerships &amp; Product ExpansionLate last month, Wellgistics announced an agreement with Tollo Health to market its proprietary medical food products, addressing the side effects of GLP-1 treatments and long-term COVID-19.&nbsp;Tollo's flagship product, Galectovid, is designed to manage dietary Galectin-1 and 3-associated viral infections, muscle loss, and gut discomfort linked to GLP-1 drug use.Earlier this month, Wellgistics partnered with Protega Pharmaceuticals, the maker of Roxybond, an FDA-approved abuse-deterrent opioid pain medication.&nbsp;The collaboration aims to enhance pharmacist education on abuse-deterrent pain management and expand access to Roxybond, particularly in underserved rural areas, via Wellgistics' independent pharmacy clients.Leadership Change &amp; Compliance MilestoneEarlier this month, Wellgistics appointed Brian Norton as its new CEO, replacing Tim Canning. Under his leadership, the company plans to improve operational efficiency, optimize sales, advance its technology roadmap, and explore acquisition opportunities.Retail investors on Stocktwits took note of Norton's Fox Business&nbsp;<a target="_blank" rel="noopener noreferrer nofollow" href="https://www.foxbusiness.com/video/6370288081112">interview</a> on Thursday, in which he said U.S. pharmacy benefit managers (PBMs) had failed to lower drug prices and instead led to rising costs.&nbsp;He said Wellgistics aims to address this by providing affordable medications and ensuring safe opioid administration.&nbsp;<stembedurl>https://stocktwits.com/Paraboljoker/message/608773239</stembedurl>Norton also advocated for scrutinizing PBMs, supporting independent pharmacies, and ensuring pricing transparency to empower patients.Since its Nasdaq debut in February, Wellgistics stock has climbed more than 8%, signaling strong investor confidence in the newcomer.&nbsp;For updates and corrections, email newsroom[at]stocktwits[dot]com.

Why Retail Traders Are Rushing Into Small-Cap Wellgistics Health Weeks After Its Nasdaq Debut

The CEO has said the company aims to address the failures of pharmacy benefit managers by providing affordable medications and ensuring safe opioid administration.

Equity

The CEO has said the company aims to address the failures of pharmacy benefit managers by providing affordable medications and ensuring safe opioid administration.


Wellgistics Health, Inc. operates as a holding company centered around pharmaceuticals and healthcare services. Its business portfolio consists of a pharmacy, wholesale operations, and a technology division with a novel platform for hub and clinical services. The company was founded by Ajjarapu Surendra on September 6, 2022 and is headquartered in Tampa, FL.

WGRX
Wellgistics Health Inc.

Feed

News

Sentiment

Fundamentals

Info

Latest WGRX News

WGRXWellgistics Health Inc.